List of Excipients in API pralsetinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing pralsetinib
Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
---|---|---|---|---|---|
Genentech Inc | GAVRETO | pralsetinib | 50242-210 | ANHYDROUS CITRIC ACID | 2036-11-01 |
Genentech Inc | GAVRETO | pralsetinib | 50242-210 | HYDROXYPROPYL CELLULOSE | 2036-11-01 |
Genentech Inc | GAVRETO | pralsetinib | 50242-210 | MAGNESIUM STEARATE | 2036-11-01 |
Genentech Inc | GAVRETO | pralsetinib | 50242-210 | SODIUM BICARBONATE | 2036-11-01 |
Rigel Pharmaceuticals Inc | GAVRETO | pralsetinib | 71332-006 | ANHYDROUS CITRIC ACID | 2036-11-01 |
Rigel Pharmaceuticals Inc | GAVRETO | pralsetinib | 71332-006 | HYDROXYPROPYL CELLULOSE | 2036-11-01 |
Rigel Pharmaceuticals Inc | GAVRETO | pralsetinib | 71332-006 | MAGNESIUM STEARATE | 2036-11-01 |
>Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for pralsetinib
Excipient focus: ALCOHOL
pralsetinib drug variants containing ALCOHOL
Company | Ingredient | NDC |
---|---|---|
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing ALCOHOL
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
>Company | >Ingredient | >NDC |
Excipient focus: AMMONIA
pralsetinib drug variants containing AMMONIA
Company | Ingredient | NDC |
---|---|---|
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing AMMONIA
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
>Company | >Ingredient | >NDC |
Excipient focus: ANHYDROUS CITRIC ACID
pralsetinib drug variants containing ANHYDROUS CITRIC ACID
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing ANHYDROUS CITRIC ACID
Company | Ingredient | NDC |
---|---|---|
>Company | >Ingredient | >NDC |
Excipient focus: BUTYL ALCOHOL
pralsetinib drug variants containing BUTYL ALCOHOL
Company | Ingredient | NDC |
---|---|---|
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing BUTYL ALCOHOL
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
>Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 1
pralsetinib drug variants containing FD&C BLUE NO. 1
Company | Ingredient | NDC |
---|---|---|
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing FD&C BLUE NO. 1
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
>Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
pralsetinib drug variants containing HYDROXYPROPYL CELLULOSE
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing HYDROXYPROPYL CELLULOSE
Company | Ingredient | NDC |
---|---|---|
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
pralsetinib drug variants containing HYPROMELLOSE 2910
Company | Ingredient | NDC |
---|---|---|
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing HYPROMELLOSE 2910
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
>Company | >Ingredient | >NDC |
Excipient focus: ISOPROPYL ALCOHOL
pralsetinib drug variants containing ISOPROPYL ALCOHOL
Company | Ingredient | NDC |
---|---|---|
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing ISOPROPYL ALCOHOL
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
>Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
pralsetinib drug variants containing MAGNESIUM STEARATE
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing MAGNESIUM STEARATE
Company | Ingredient | NDC |
---|---|---|
>Company | >Ingredient | >NDC |
Excipient focus: MICROCRYSTALLINE CELLULOSE 102
pralsetinib drug variants containing MICROCRYSTALLINE CELLULOSE 102
Company | Ingredient | NDC |
---|---|---|
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing MICROCRYSTALLINE CELLULOSE 102
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
>Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
pralsetinib drug variants containing POLYVINYL ALCOHOL
Company | Ingredient | NDC |
---|---|---|
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing POLYVINYL ALCOHOL
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
>Company | >Ingredient | >NDC |
Excipient focus: POTASSIUM HYDROXIDE
pralsetinib drug variants containing POTASSIUM HYDROXIDE
Company | Ingredient | NDC |
---|---|---|
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing POTASSIUM HYDROXIDE
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
>Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
pralsetinib drug variants containing PROPYLENE GLYCOL
Company | Ingredient | NDC |
---|---|---|
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing PROPYLENE GLYCOL
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
>Company | >Ingredient | >NDC |
Excipient focus: SHELLAC
pralsetinib drug variants containing SHELLAC
Company | Ingredient | NDC |
---|---|---|
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing SHELLAC
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
>Company | >Ingredient | >NDC |
Excipient focus: SODIUM BICARBONATE
pralsetinib drug variants containing SODIUM BICARBONATE
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing SODIUM BICARBONATE
Company | Ingredient | NDC |
---|---|---|
>Company | >Ingredient | >NDC |
Excipient focus: STARCH, CORN
pralsetinib drug variants containing STARCH, CORN
Company | Ingredient | NDC |
---|---|---|
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing STARCH, CORN
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
>Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
pralsetinib drug variants containing TITANIUM DIOXIDE
Company | Ingredient | NDC |
---|---|---|
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing TITANIUM DIOXIDE
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
>Company | >Ingredient | >NDC |
Excipient focus: WATER
pralsetinib drug variants containing WATER
Company | Ingredient | NDC |
---|---|---|
Blueprint Medicines Corporation | pralsetinib | 72064-210 |
>Company | >Ingredient | >NDC |
pralsetinib drug variants not containing WATER
Company | Ingredient | NDC |
---|---|---|
Genentech Inc | pralsetinib | 50242-210 |
Rigel Pharmaceuticals Inc | pralsetinib | 71332-006 |
>Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.